Celltrion And Pfizer Cement Victory On Infliximab

Janssen's Cell-Culture Media Patent Not Infringed By Inflectra/Remsima

Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.

Gavel
Celltrion and Pfizer have the backing of an appeals court for their biosimilar infliximab • Source: Shutterstock

Celltrion and Pfizer’s Hospira have cemented a legal victory for their Inflectra/Remsima (infliximab-dyyb) biosimilar in the US, with a Court of Appeals affirming that the cell-culture media they use to produce the biosimilar of Janssen’s Remicade (infliximab) does not infringe the originator’s intellectual property.

In a one-page ruling, Federal Circuit judges Evan Wallach, Richard Taranto and Kara Stoll affirmed per curiam a Massachusetts district...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin